We are analyzing https://link.springer.com/article/10.1007/s12032-014-0263-6.

Title:
Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy | Medical Oncology
Description:
microRNA-133a (miR-133a) and miR-133b, located on chromosome 18 in the same bicistronic unit, have been commonly identified as being downregulated in esophageal squamous cell carcinoma (ESCC). The aim of this study was to investigate the correlation of miR-133a/b expression with efficacy of paclitaxel-based chemotherapy and clinical outcome of ESCC patients. miR-133a expression and miR-133b expression were examined in 100 newly diagnosed ESCC patients prior to treatment by quantitative real-time PCR. Then, the patients received four cycles of paclitaxel-based chemotherapy, the short-term treatment efficacy was evaluated, and a 3-year follow-up was performed. Expression levels of miR-133a and miR-133b were both significantly lower in ESCC tissues compared to adjacent noncancerous tissues (both P < 0.001). In addition, combined miR-133a/b downregulation was found to be closely correlated with advanced tumor stage (P = 0.02) and poor differentiation (P = 0.01). Moreover, the response rate of ESCC patients to paclitaxel-based chemotherapy was significantly higher in combined miR-133a/b downregulation group compared with other groups (P = 0.02). Furthermore, univariate and multivariate Cox analyses revealed that tumor stage and combined expression of miR-133a/b were independent prognosis factors in ESCC patients. Our data offer the convincing evidence that combined expression of miR-133a and miR-133b may predict chemosensitivity of patients with ESCC undergoing paclitaxel-based chemotherapy, implying its importance in applying ‘personalized cancer medicine’ in the clinical treatment of ESCC. We also identified combined expression of miR-133a and miR-133b as an effective prognostic marker of this malignancy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Telecommunications
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

pubmed, article, google, scholar, cell, cancer, carcinoma, esophageal, squamous, central, cas, wang, expression, patients, chen, mirb, zhou, escc, mira, microrna, zhang, micrornaa, paclitaxelbased, chemotherapy, combined, access, oncol, treatment, tumor, privacy, cookies, content, chemosensitivity, jin, invasion, seki, yang, lin, data, information, publish, research, search, downregulation, micrornab, peng, zhu, mirab, prognosis, prognostic,

Topics {✒️}

quantitative real-time pcr microrna-10b-3p targets foxo3 month download article/chapter xilei zhou & wanwei wang microrna-133b predicts chemosensitivity paclitaxel-based chemotherapy related subjects short-term treatment efficacy paclitaxel-based chemoradiation cancer cell proliferation lian’shui county people full article pdf mir-133a tumor suppressor cell biochem biophys nanjing medical university privacy choices/manage cookies tumour suppressor mir-133b drug combination chemotherapy independent prognosis factors cell death dis colorectal cancer cells cervical carcinoma development negatively regulates tbpl1 recurrent prostate cancer human cancers downregulation group compared gastric cancer cells regulating myoblast proliferation microrna-206/133b clusters mir-133a target bmc cancer advanced tumor stage european economic area adjacent noncancerous tissues check access expert opin pharmacother oral maxillofac res curr drug targets erk1/2 pathway involving downstream effector proteins purine nucleoside phosphorylase improved local control instant access esophageal cancer colorectal cancer patients combined mir-133a/ altered mirna expression conditions privacy policy embo mol med pharmgenomics pers med

Questions {❓}

Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy
         description:microRNA-133a (miR-133a) and miR-133b, located on chromosome 18 in the same bicistronic unit, have been commonly identified as being downregulated in esophageal squamous cell carcinoma (ESCC). The aim of this study was to investigate the correlation of miR-133a/b expression with efficacy of paclitaxel-based chemotherapy and clinical outcome of ESCC patients. miR-133a expression and miR-133b expression were examined in 100 newly diagnosed ESCC patients prior to treatment by quantitative real-time PCR. Then, the patients received four cycles of paclitaxel-based chemotherapy, the short-term treatment efficacy was evaluated, and a 3-year follow-up was performed. Expression levels of miR-133a and miR-133b were both significantly lower in ESCC tissues compared to adjacent noncancerous tissues (both P < 0.001). In addition, combined miR-133a/b downregulation was found to be closely correlated with advanced tumor stage (P = 0.02) and poor differentiation (P = 0.01). Moreover, the response rate of ESCC patients to paclitaxel-based chemotherapy was significantly higher in combined miR-133a/b downregulation group compared with other groups (P = 0.02). Furthermore, univariate and multivariate Cox analyses revealed that tumor stage and combined expression of miR-133a/b were independent prognosis factors in ESCC patients. Our data offer the convincing evidence that combined expression of miR-133a and miR-133b may predict chemosensitivity of patients with ESCC undergoing paclitaxel-based chemotherapy, implying its importance in applying ‘personalized cancer medicine’ in the clinical treatment of ESCC. We also identified combined expression of miR-133a and miR-133b as an effective prognostic marker of this malignancy.
         datePublished:2014-10-04T00:00:00Z
         dateModified:2014-10-04T00:00:00Z
         pageStart:1
         pageEnd:8
         sameAs:https://doi.org/10.1007/s12032-014-0263-6
         keywords:
            microRNA-133
            Esophageal squamous cell carcinoma
            Chemosensitivity
            Prognosis
            Quantitative real-time PCR
            Oncology
            Hematology
            Pathology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-014-0263-6/MediaObjects/12032_2014_263_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-014-0263-6/MediaObjects/12032_2014_263_Fig2_HTML.gif
         isPartOf:
            name:Medical Oncology
            issn:
               1559-131X
               1357-0560
            volumeNumber:31
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Guiming Chen
               affiliation:
                     name:Lian’shui County People’s Hospital
                     address:
                        name:Department of Thoracic Surgery, Lian’shui County People’s Hospital, Lian’shui, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jin Peng
               affiliation:
                     name:Nanjing Medical University
                     address:
                        name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Weiguo Zhu
               affiliation:
                     name:Nanjing Medical University
                     address:
                        name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Guangzhou Tao
               affiliation:
                     name:Nanjing Medical University
                     address:
                        name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yaqi Song
               affiliation:
                     name:Nanjing Medical University
                     address:
                        name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Xilei Zhou
               affiliation:
                     name:Nanjing Medical University
                     address:
                        name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wanwei Wang
               affiliation:
                     name:Nanjing Medical University
                     address:
                        name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy
      description:microRNA-133a (miR-133a) and miR-133b, located on chromosome 18 in the same bicistronic unit, have been commonly identified as being downregulated in esophageal squamous cell carcinoma (ESCC). The aim of this study was to investigate the correlation of miR-133a/b expression with efficacy of paclitaxel-based chemotherapy and clinical outcome of ESCC patients. miR-133a expression and miR-133b expression were examined in 100 newly diagnosed ESCC patients prior to treatment by quantitative real-time PCR. Then, the patients received four cycles of paclitaxel-based chemotherapy, the short-term treatment efficacy was evaluated, and a 3-year follow-up was performed. Expression levels of miR-133a and miR-133b were both significantly lower in ESCC tissues compared to adjacent noncancerous tissues (both P < 0.001). In addition, combined miR-133a/b downregulation was found to be closely correlated with advanced tumor stage (P = 0.02) and poor differentiation (P = 0.01). Moreover, the response rate of ESCC patients to paclitaxel-based chemotherapy was significantly higher in combined miR-133a/b downregulation group compared with other groups (P = 0.02). Furthermore, univariate and multivariate Cox analyses revealed that tumor stage and combined expression of miR-133a/b were independent prognosis factors in ESCC patients. Our data offer the convincing evidence that combined expression of miR-133a and miR-133b may predict chemosensitivity of patients with ESCC undergoing paclitaxel-based chemotherapy, implying its importance in applying ‘personalized cancer medicine’ in the clinical treatment of ESCC. We also identified combined expression of miR-133a and miR-133b as an effective prognostic marker of this malignancy.
      datePublished:2014-10-04T00:00:00Z
      dateModified:2014-10-04T00:00:00Z
      pageStart:1
      pageEnd:8
      sameAs:https://doi.org/10.1007/s12032-014-0263-6
      keywords:
         microRNA-133
         Esophageal squamous cell carcinoma
         Chemosensitivity
         Prognosis
         Quantitative real-time PCR
         Oncology
         Hematology
         Pathology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-014-0263-6/MediaObjects/12032_2014_263_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12032-014-0263-6/MediaObjects/12032_2014_263_Fig2_HTML.gif
      isPartOf:
         name:Medical Oncology
         issn:
            1559-131X
            1357-0560
         volumeNumber:31
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Guiming Chen
            affiliation:
                  name:Lian’shui County People’s Hospital
                  address:
                     name:Department of Thoracic Surgery, Lian’shui County People’s Hospital, Lian’shui, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jin Peng
            affiliation:
                  name:Nanjing Medical University
                  address:
                     name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Weiguo Zhu
            affiliation:
                  name:Nanjing Medical University
                  address:
                     name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Guangzhou Tao
            affiliation:
                  name:Nanjing Medical University
                  address:
                     name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yaqi Song
            affiliation:
                  name:Nanjing Medical University
                  address:
                     name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Xilei Zhou
            affiliation:
                  name:Nanjing Medical University
                  address:
                     name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wanwei Wang
            affiliation:
                  name:Nanjing Medical University
                  address:
                     name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Medical Oncology
      issn:
         1559-131X
         1357-0560
      volumeNumber:31
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Lian’shui County People’s Hospital
      address:
         name:Department of Thoracic Surgery, Lian’shui County People’s Hospital, Lian’shui, China
         type:PostalAddress
      name:Nanjing Medical University
      address:
         name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
         type:PostalAddress
      name:Nanjing Medical University
      address:
         name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
         type:PostalAddress
      name:Nanjing Medical University
      address:
         name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
         type:PostalAddress
      name:Nanjing Medical University
      address:
         name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
         type:PostalAddress
      name:Nanjing Medical University
      address:
         name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
         type:PostalAddress
      name:Nanjing Medical University
      address:
         name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Guiming Chen
      affiliation:
            name:Lian’shui County People’s Hospital
            address:
               name:Department of Thoracic Surgery, Lian’shui County People’s Hospital, Lian’shui, China
               type:PostalAddress
            type:Organization
      name:Jin Peng
      affiliation:
            name:Nanjing Medical University
            address:
               name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
               type:PostalAddress
            type:Organization
      name:Weiguo Zhu
      affiliation:
            name:Nanjing Medical University
            address:
               name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
               type:PostalAddress
            type:Organization
      name:Guangzhou Tao
      affiliation:
            name:Nanjing Medical University
            address:
               name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
               type:PostalAddress
            type:Organization
      name:Yaqi Song
      affiliation:
            name:Nanjing Medical University
            address:
               name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
               type:PostalAddress
            type:Organization
      name:Xilei Zhou
      affiliation:
            name:Nanjing Medical University
            address:
               name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
               type:PostalAddress
            type:Organization
      name:Wanwei Wang
      affiliation:
            name:Nanjing Medical University
            address:
               name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Thoracic Surgery, Lian’shui County People’s Hospital, Lian’shui, China
      name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
      name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
      name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
      name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
      name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
      name:Department of Radiotherapy, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(142)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.29s.

LINK . SPRINGER . COM {}